In April 2005, Spectrum entered into an exclusive agreement with Cura Pharmaceutical Co., Inc. for the marketing and distribution of carboplatin injection in the US market. Distribution began in July, 2005 following FDA approval of Spectrum's carboplatin injection ANDA on June 16, 2005.
Cura Pharmaceutical Co., Inc is a pharmaceutical marketing company that focuses on select niche specialty markets through the offering of distinctive products and services that present efficiency and/or cost effectiveness. Cura's strategy is to provide poducts to the American Healthcare Practioner that satisfy a distinct unmet medical need, ofer products not readily assessible and provide ehnancements to existing treatments. Cura management has extensive experience in the oncology market with over 100 years of combined experience. Cura management is very familiar and cognizant of this market, and knows its players intimately.
Spectrum believes that this alliance has the potential to speed our entry into the generic oncology marketplace where Cura's experienced sales executives have established relationships and thus the ability to create sales opportunities for carboplatin injection.
For carboplatin ordering information,
click here.
